Venti Amanda, Giordano Tony, Eder Paul, Bush Ashley I, Lahiri Debomoy K, Greig Nigel H, Rogers Jack T
Genetics and Aging Research Unit, Department of Psychiatry, Massachusetts General Hospital East, Charlestown, MA 02129, USA.
Ann N Y Acad Sci. 2004 Dec;1035:34-48. doi: 10.1196/annals.1332.003.
The Alzheimer's amyloid precursor protein (APP) is the metalloprotein that is cleaved to generate the pathogenic Abeta peptide. We showed that iron closely regulated the expression of APP by 5'-untranslated region (5'-UTR) sequences in APP mRNA. Iron modulated APP holoprotein expression by a pathway similar to iron control of the translation of the ferritin-L and -H mRNAs by iron-responsive elements in their 5'-UTRs. APP gene transcription is also responsive to copper deficit where the Menkes protein depleted fibroblasts of copper to suppress transcription of APP through metal regulatory and copper regulatory sequences upstream of the APP 5' cap site. APP is a copper-zinc metalloprotein and chelation of Fe(3+) by desferrioxamine and Cu(2+) by clioquinol appeared to provide effective therapy for the treatment of AD in limited patient studies. We have introduced an RNA-based screen for small APP 5'-UTR binding molecules to identify leads that limit APP translation (but not APLP-1 and APLP-2) and amyloid Abeta peptide production. A library of 1200 drugs was screened to identify lead drugs that limited APP 5'-UTR-directed translation of a reporter gene. The efficacy of these leads was confirmed for specificity in a cell-based secondary assay to measure the steady-state levels of APP holoprotein relative to APLP-1/APLP-2 by Western blotting. Several chelators were identified among the APP 5'-UTR directed leads consistent with the presence of an IRE stem-loop in front of the start codon of the APP transcript. The APP 5'-UTR-directed drugs--desferrioxamine (Fe(3+) chelator), tetrathiomolybdate (Cu(2+) chelator), and dimercaptopropanol (Pb(2+) and Hg(2+) chelator)--each suppressed APP holoprotein expression (and lowered Abeta peptide secretion). The novel anticholinesterase phenserine also provided "proof of concept" for our strategy to target the APP 5'-UTR sequence to identify "anti-amyloid" drugs. We further defined the interaction between iron chelation and phenserine action to control APP 5'-UTR-directed translation in neuroblastoma (SY5Y) transfectants. Phenserine was most efficient to block translation under conditions of intracellular iron chelation with desferrioxamine suggesting that this anticholinesterase operated through an iron (metal)-dependent pathway at the APP 5'-UTR site.
阿尔茨海默病淀粉样前体蛋白(APP)是一种金属蛋白,其被切割后会产生致病性β淀粉样肽。我们发现,铁通过APP mRNA中的5'非翻译区(5'-UTR)序列紧密调控APP的表达。铁通过类似于铁通过铁反应元件控制铁蛋白-L和-H mRNA翻译的途径来调节APP全蛋白的表达,这些铁反应元件位于它们的5'-UTR中。APP基因转录也对铜缺乏有反应,在这种情况下,门克斯蛋白使成纤维细胞中的铜耗竭,从而通过APP 5'帽位点上游的金属调节和铜调节序列抑制APP的转录。APP是一种铜锌金属蛋白,在有限的患者研究中,去铁胺对Fe(3+)的螯合以及氯碘羟喹对Cu(2+)的螯合似乎为治疗阿尔茨海默病提供了有效的疗法。我们引入了一种基于RNA的筛选方法,用于筛选与APP 5'-UTR结合的小分子,以鉴定能够限制APP翻译(但不影响APLP-1和APLP-2)以及淀粉样β肽产生的先导化合物。对一个包含1200种药物的文库进行筛选,以鉴定能够限制报告基因的APP 5'-UTR指导翻译的先导药物。在基于细胞的二次试验中,通过蛋白质印迹法测量APP全蛋白相对于APLP-1/APLP-2的稳态水平,证实了这些先导化合物的特异性疗效。在APP 5'-UTR指导的先导化合物中鉴定出了几种螯合剂,这与APP转录本起始密码子前存在铁反应元件茎环结构一致。APP 5'-UTR指导的药物——去铁胺(Fe(3+)螯合剂)、四硫钼酸盐(Cu(2+)螯合剂)和二巯丙醇(Pb(2+)和Hg(2+)螯合剂)——均抑制了APP全蛋白的表达(并降低了β淀粉样肽的分泌)。新型抗胆碱酯酶药物苯丝氨酸也为我们针对APP 5'-UTR序列来鉴定“抗淀粉样”药物的策略提供了“概念验证”。我们进一步确定了铁螯合与苯丝氨酸作用之间的相互作用,以控制神经母细胞瘤(SY5Y)转染细胞中APP 5'-UTR指导的翻译。在与去铁胺进行细胞内铁螯合的条件下,苯丝氨酸在阻断翻译方面最为有效,这表明这种抗胆碱酯酶通过APP 5'-UTR位点的铁(金属)依赖性途径发挥作用。